The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
DsbA Foldases From Multidrug Resistant Pathogens As Targets For New Antimicrobials
Funder
National Health and Medical Research Council
Funding Amount
$743,401.00
Summary
Bacteria that cause common human infections, such as cystitis and diarrhoea, are now resistant to many antibiotics. If no action is taken, by 2050 antibiotic resistant infections will kill more people each year than cancer. This project aims to address this global public health crisis by characterising promising new bacterial targets and inhibitors designed to disarm multidrug resistant pathogens. Longer term this work could provide new infection therapies that are urgently needed.
An Integrated Approach To Combat Antibiotic Resistance
Funder
National Health and Medical Research Council
Funding Amount
$389,120.00
Summary
The development of antibiotics such as penicillin was hailed as one of the great breakthroughs in medicine. However, an increasing number of pathogens have acquired resistance to these drugs. One of the most common resistance mechanisms employed by these pathogens is the use of metal dependent enzymes that promote the degradation of antibiotics. To date, no clinically useful inhibitors for these enzymes are available. In this project, we aim to develop such inhibitors as therapeutic drug leads.
Preventing The Evolution Of Transmissible Nitroimidazole Resistance In Mycobacterium Tuberculosis
Funder
National Health and Medical Research Council
Funding Amount
$664,463.00
Summary
Tuberculosis kills more people than any other infectious disease. Unfortunately, the drugs available to us to treat TB are losing their efficacy due to the evolution of drug resistance. A new class of drugs, nitroimidazoles, has been developed, but there is a risk that the bacterium that causes TB will develop resistance to these compounds too. We will identify resistance mutations before they occur in the wild, to help identify them and find new compounds for which resistance cannot develop.
Development Of Novel Anticoagulants Inspired By Nature For Improved Ischaemic Stroke Therapy
Funder
National Health and Medical Research Council
Funding Amount
$716,396.00
Summary
Ischaemic stroke, caused by clots that obstruct blood flow to the brain, is the third most common cause of mortality and the leading cause of disability globally. Unfortunately, the only approved therapeutic option is ineffective for a significant proportion of stroke sufferers. This project will develop novel anticoagulants, inspired by molecules produced by blood feeding organisms, for use in more effective and safe ischaemic stroke therapy.
Flaviviral Proteases As Viable Targets For Antiinfective Drugs
Funder
National Health and Medical Research Council
Funding Amount
$620,716.00
Summary
Viruses hijack the machinery and nutrients of cells they infect in order to reproduce. We will study viral enzymes (proteases) essential for virus replication, use fluorescent probes to learn where the viral enzymes hide and act in infected cells, track the passage of drugs aimed at these enzymes, design drugs to block their actions and stop virus replication, and test antiviral activity against Dengue, West Nile, Japanese Encephalitis and Yellow Fever viruses which infect millions of people.
Disruption Of Proteolytic Cascades In The Skin:towards Halting The Atopic March
Funder
National Health and Medical Research Council
Funding Amount
$388,601.00
Summary
There are over 3000 named skin disorders which range in severity from the trivial including acne, to life threatening such as skin cancer. Many skin diseases result from a lack of control over the way the skin maintains itself. Cutting the connections that hold cells together is key to balancing loss of skin cells with their continuous replacement. This project focuses on making compounds to block skin cell shedding with the longer term aim of producing novel drugs to treat skin disease.
Biochemical Investigation Of Ubiquitination By The Fanconi Anaemia Pathway
Funder
National Health and Medical Research Council
Funding Amount
$603,447.00
Summary
Fanconi anaemia is an inherited disorder with greatly elevated risk of leukaemia and cancers. The causal genes are ‘tumour suppressors’ that protect us from cancer by a complex function in repair of damage to our DNA. This study aims to understand how this DNA repair function protects us from cancer, and may influence some forms of new forms of cancer treatment.
Redox Control Of The Immune Regulatory Protein, Indoleamine 2,3-dioxygenase
Funder
National Health and Medical Research Council
Funding Amount
$576,538.00
Summary
An enzyme called indoleamine 2,3-dioxygenase is important for controlling the immune system during normal and disease conditions including pregnancy, cancer, inflammation and infectious disease. Despite its importance little is known about how this enzyme is controlled. This project will provide important new insights into how this enzyme is regulated. Such fundamental scientific information can discover new ways in which to alter the enzyme's activity in order to modulate immune responses.
Towards Alternative Therapeutic Agents To Antibiotics For The Treatment Of Helicobacter Pylori Infections.
Funder
National Health and Medical Research Council
Funding Amount
$787,286.00
Summary
The bacterium H. pylori, is the leading cause of gastric ulcers, infecting over half of the world population. Furthermore, patients infected with the bacteria exhibit an increased risk of developing gastric cancer, with 900,000 new cases diagnosed yearly. The current proposal will study an enzyme which allows the bacterium to evade the host's immune system. The work aims to develop inhibitors of the enzyme as therapeutic agents to treat peptic ulcers.
Biochemical Reconstitution Of The Ubiquitin Ligase Pathway Defective In Fanconi Anaemia
Funder
National Health and Medical Research Council
Funding Amount
$562,742.00
Summary
Fanconi Anemia (FA) is characterised by loss of vital blood cells but also 700x risk of developing leukaemia and other cancers. FA is caused by an inherited defect in one of 15 different genes that provide a signal and repair mechanism protecting cells from cancer causing mutations. By reconstructing this signaling mechanism in the test tube we will determine how it contributes to cancer protection, and highlight potential strategies for treatment of FA and leukaemia in the general population.